We present a radioimmunoassay for lysozyme In human serum, based upon human lysozyme isolated from the urine of leukemic patients and antiserum prepared against this lysozyme in the goat. In the separation step, a second antibody is used. By properly adjusting the concentrations of unlabeled and 1251-labeled lysozyme and of the antibodies, maximal precision (SD, 0.04 mg/litre) was obtained In the range 0.00 to 2.00 mg/litre. In 20 normal volunteers the lysozyme concentration was 4.6 ± 0.8 mg/litre (mean ± SD), in 13 patients with monocytic leukemia 34.4 ± 8.6 mg/litre. Correlation with lysoplate determinations was excellent in leukemic sera (r = 0.97) but was poor in normal sera (r = 0.35), possibly owing to the existence of isoenzymes. were evoked as the cause of the observed discrepancies (4-6). The use of different standards and conventions in converting or expressing lysozyme activities into quantities has added to the confusion. In view of these problems, we decided to develop a radioimmunoassay for human lysozyme.
was obtained from IRE, Fleurus (Belgium), lactoperoxidase (EC 1.11.1.7) and hen's egg-white lysozyme from Sigma Chemical Co., St. Louis, Mo. 63178. The goat antihuman lysozyme and the rabbit antigoat immunoglobulin antiserum were from Nordic Pharmaceuticals and Diagnostics, Berchem, Belgium.
Lysop late Assay
For lysoplate determinations (6) we used gels (10 g of agarose per litre) containing per litre, 0.6 g of Micrococcus lysodeikticus and 66 mmol of phosphate, pH 6.6. We used a sample volume of 10 ILl.
lodination of Human Lysozyme
Jodination was done by the lactoperoxidase method (8) 
Radloimmunoassay
To set up the radioimmunoassay, we adjusted the specific activity of the labeled lysozyme to 0.14 ,zCi/ng by adding unlabeled enzyme. In assay mixtures a total of 10 000 cpm 1251 was used, corresponding to 50 ng of human lysozyme. A dilution curve of the antiserum was prepared according to usual procedures.
A binding of 53% was observed with a 200-fold dilution, which was therefore selected as the working dilution.
The radioimmunoassay mixture always consisted of 100 zl of goat antihuman lysozyme (200-fold dilution), 100 l of either sample, standard or buffer, 100 l of iodinated lysozyme (50 ng), and 100 l of assay buffer.
The assay buffer, which also was used for all necessary dilutions, was barbiturate-HC1
(20 mmol/litre, pH 7.2) containing, per litre, 40 g of bovine serum albumin and 0.1 mCi of 22Na. After a 24-h incubation at 4 #{176}C, 50 zl of goat 7-globulins (suitably diluted) was added, followed by 50 Mlof rabbit antigoat 7-globulins. This mixture was incubated for an additional 2 h at 25 #{176}C, and, after 800 d of cold NaC1 solution (9g/litre) was added, was centrifuged at 2000 X g for 30 mm. Incubation period: 2h,25#{176}C
to 550 keV. The spill-over of 22Na counts in the 1251 channel was determined in every assay, and amounted to approximately 0.14. 125J counts were corrected accordingly and 1251 counts in precipitate and supernate were calculated, assuming a uniform distribution of 22Na in the soluble phase. The standard curve was prepared by adding 0,0.025, 0.05,0.1,0.2, 0.4, and 0.8 tg of human lysozyme in 100 Ml of buffer containing bovine serum albumin (40 g/litre). Unknowns were routinely diluted threefold in buffer containing albumin. Sera from leukemia patients were diluted, based upon results of their lysoplate determinations, so as to fall within roughly the same assay range. The amount of carrier goat 7-globulins added in the separation phase was separately determined in every experiment.
To different tubes, containing the mixture for which maximal complex formation was expected, various amounts of carrier goat 7-globulins were added, followed by 50 Ml of rabbit anti-goat 7-globulins. The amount giving maximal precipitation was then used for the assay. The procedure is summarized in Figure 1 .
Results
Separation of the labeling mixture on Sephadex G-10 is shown in Figure 2 . The first peak, corresponding to lysozyme, contained 49% of the total eluted radioactivity.
These fractions were combined, and from a determination of the lysozyme concentration by the lysoplate method the specific activity was computed to be 0.6 Ci/g. The specific activity was decreased to 0.14 Ci/g by addition of nonlabeled enzyme. Total lysozyme concentration was 0.5 mg/litre, and 100 l of this solution was used in the radioimmunoassays.
A typical standard curve is shown in Figure 3 . Precision was computed from the differences between duplicates. For the standard curve the standard error of the experimental parameter 
Discussion
The most surprising and at first sight probably disappointing feature of our radioimmunoassay for human lysozyme is its low sensitivity.
There are several reasons for this.
When we attempted to iodinate lysozyme at high specific activity, the product was immunologically unreactive. With the Chloramine T method we never obtained a satisfactory product. With the lactoperoxidase method described in this All values in mg/litre paper a specific activity of 9 kCi/mol is achieved, but if all six tyrosines of human lysozyme were monoiodinated the specific activity could be 12.6 MCi/mol.
However, to measure lysozyme in biological fluids such high sensitivity is not required and might even be a disadvantage. With our labeling procedure, and assuming a total of 10 000 cpm in the assay mixture, the amount of labeled product used in the assay would be about lOng, and corresponding amounts could be measured. In serum the normal range is 3.0 to 6.2 mg/litre, or 300 to 620 ng/100 Ml, and a dilution of at least 20-fold would be required before the assay. A compromise was sought by decreasing the specific activity to 0.14 Ci/g. With 10000 cpm in the assay, the zero standard contains 50 ng. The resulting standard curve had highest sensitivity in the 0-2 mg/litre range (0-200 ng in the assay), and even this requires a threefold dilution of most serum samples.
Another unusual feature of our assay system is the high albumin concentration. Initially no albumin was added. In comparison with the present procedure, the percentage of label precipitated by the second antibody was then 3-5% greater in all standards, and in a blank prepared without antibody, nonspecific precipitation was higher than the zero standard! Apparently, lysozyme was denatured during incubation, but was partly protected against denaturation by antibody. Addition of bovine serum albumin at a concentration of 4% protected the blanks, standards, and samples from denaturation (nonspecific precipitation lower than 5%). The correlation studies with lysoplate determinations raise an important point. Although the concentration range in leukemia patients and normals is quite different, a different precision of the assays at different concentrations cannot be responsible for the low correlation in normal individuals, because leukemia sera were first diluted to the normal range and then tested by both lysoplate and radioimmunoassay. Our findings could be explained by the existence of lysozyme isoenzymes. In patients with monocytic leukemia the high lysozyme concentration is certainly of monocytic origin and is correctly measured by a radioimmunassay based upon such lysozyme, but in normal people other sources could contribute to the serum lysozyme. Because antibodies against monocytic lysozyme have been used to localize lysozyme in several tissues (9, 12) lysozymes from different tissues show at least cross reactivity with monocytic lysozyme. However, this does not exclude the possibility that on a quantitative basis their reactivity in radioimmunoassay could be less.
Recently, evidence has been presented for the existence of lysozyme isoenzymes in the urine of patients with monocytic leukemia (13) . We have already suggested that the poor correlation between turbidimetric and lysoplate determinations could be due to the presence of isoenzymes, because in these methods a different criterion determines the final result: in the turbidimetric determination lytic activity is measured, the lysoplate method measures the diffusion zone produced by lysis (5) . Such an hypothesis is difficult to substantiate by these methods, because it currently is impossible separately to measure lytic activity or diffusion from the supposed isoenzymes. Similarly, owing to the cross reactivities to be expected between lysozyme isoenzymes in man, a discrimination by radioimmunoassay might prove to be difficult. However, in view of the possible diagnostic implications, efforts should be continued in this direction.
Our radioimmunoassay is a clear improvement over methods based upon activity measurements such as the turbidimetric method and the lysoplate method, which are so easily influenced by assay conditions (14) . Also, no other immunologic method matches the precision and accuracy of radioimmunoassay. However, as in any immunologic phenomenon, only the antigen corresponding to the antibody used is detected.
